Tscan therapeutics announces upcoming oral presentation of data from the alloha™ phase 1 heme trial at the 66th american society of hematology annual meeting and exposition

All tsc-treated patients were relapse-free and mrd negative as of data cutoff tsc-100 and tsc-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with aml, all, or mds undergoing allogeneic hct with reduced intensity conditioning company to host virtual kol event featuring ran reshef, m.d., m.sc., on tuesday, december 10, at 8:00 a.m.
TCRX Ratings Summary
TCRX Quant Ranking